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Our data clearly show why priming of CTL with minimal peptide-epitopes in IFA is suboptimal and demonstrates that the use of longer versions of these CTL peptide-epitopes ensures the induction of sustained effector CD8 + T-cell reactivity in vivo.
INTRODUCTION
Tumor cells express tumor associated antigens (TAA) on their cell surface in the context of MHC class I molecules. These TAA can be recognized by CD8 + T-cells, which are the essential players in the clearance of tumor cells in vivo (1, 2) . In recent years many epitopes have been identified (3, 4) , providing the option to apply these minimal MHC class I restricted CD8 + T-cell peptide-epitopes in vaccination strategies for the immunotherapy of solid tumors (3, 4) . Unfortunately, these minimal CTL peptide-based vaccines in oil-in-water formulations (e.g. IFA or Montanide) have in general met with limited immunological and clinical success (4, 5) .
The use of minimal CTL peptide-based vaccines was based on murine studies demonstrating that prophylactic vaccinations with minimal CTL peptides in IFA induced protective CD8 + T-cell (anti-tumor) immunity (6) (7) (8) (9) . However, other reports show that vaccination with the minimal CD8 + T-cell epitopes can also result in the induction of CD8 + T-cell tolerance (8, (10) (11) (12) (13) (14) . While in some of these studies tolerance was the result of repetitive vaccination with high dose of Ag (8, 13, 14) , others reported that even after a single subcutaneous vaccination, tolerance could be induced (11, 12) . In these studies the injection of mice with low amounts of Adenovirus E1A (11) or E1B (12) minimal CTL peptide emulsified in IFA resulted in functional impairment of activated CD8 + T-cells, as was evident from the enhanced outgrowth of tumors (11, 12) . Intravenous co-injection of agonistic CD40 antibody (FGK), in order to activate and to mature dendritic cells (DC) (15, 16) , resulted in a transient adenovirus-specific CD8 + effector T-cell response, detectable 10 days after vaccination but not at 30 days after vaccination, and did not protect mice against a tumor challenge (17).
These data indicate that an initial proper activation of the CD8 + T-cell response by minimal CTL peptide vaccines in IFA does not ensure long-term effectiveness of these CD8 + T-cells.
Such long-term effectiveness is particularly important to control chronic diseases such as cancer.
So far it is unclear what the common long-term result is with respect to immunological outcome of injection with minimal CTL peptides. Therefore, we have thoroughly studied different peptide vaccinations strategies using the highly immunogenic model Ag Ovalbumin (OVA) (18) (19) (20) (21) (22) , containing the MHC class I restricted CD8 + T-cell epitope OVA 257-264 (OVA8) and the CD4 + T helper (Th) cell epitope OVA 323-339 (ThOVA17). Peptides were mixed in IFA, as oil-in-water formulations are standard vehicles for peptide vaccination in clinical trials.
The efficacy of the different peptide vaccine formulations was tested by the analysis of the following three important parameters: i) the magnitude of the CD8 + T-cell response, ii) the ability of CD8 + T-cells to undergo secondary expansion upon antigen challenge in vitro (23) , and iii) the in vivo killing capacity of the CD8 + T-cells. These parameters were tested at either day 10 (peak of the response) or at day 30 after vaccination -the time point where adenovirus-specific CD8 + T-cells were tolerized after injection with E1A-peptide in IFA (17) .
Furthermore, we investigated how to formulate a peptide-based vaccine that triggers CTL immunity without the risk for exhaustion/tolerance.
Here, we report that vaccination with immunogenic OVA8 peptide in IFA also results in the activation of effector CD8 + T-cells which eventually ceased to expand or to kill target cells. This cessation of T-cell function was associated with long-term systemic presentation of the minimal CTL peptide in vivo but could be prevented by either complementation with a minimal T helper peptide or by extension of the minimal CTL peptide to a 30 amino acid long peptide. These data clearly shows the potential hazard of using minimal CTL peptide vaccines, and the benefits of long peptide vaccines for the induction of an effective CD8 + T-cell response.
MATERIALS AND METHODS
Mice. C57BL/6 (B6; H-2 b ) and MHC Class II knock out mice (class II-/-) mice were purchased from Charles River (St. Germain sur l'Arbresle, France). CD90.1 mice were bred at TNO-PG (Leiden, the Netherlands). CD45.1 OT-1 (24) and OT-2 (25) mice are CD8 + T-cell and CD4 + T-cell TCR transgenic (Tg) mice expressing the TCR α-chain and β-chain recognizing OVA 257-264 in H2-K b and OVA 323-339 in I-A b , respectively and were bred at the Leiden University Medical Centre animal facility. All mice were kept at the Leiden University Medical Centre animal facility and used at 8-14 weeks of age in accordance with national legislation and under supervision of the animal experimental committee of the University of Leiden.
Cell lines. EG7 (EL4-OVA) (26) tumor cells were cultured in IMDM (Invitrogen Life
Technologies, Rockville, MD) supplemented with 8% (v/v) FCS (Greiner), 50 μM 2-mercaptoethanol, 2 mM glutamine, 100 IU/ml penicillin (complete medium) and 400 ug/ ml Geneticin (Gibco).
Peptides and peptide vaccination. Peptides were generated as described before (6 In vitro stimulation. EG7 cells were incubated with 50 ug/ml of mitomycin C (Kyowa) in complete medium at 37º C for 1 hour. Subsequently, the cells were washed 4 times and then irradiated (4000 RAD). 1*10 6 EG7 cells were incubated with 10*10 6 splenocytes (V tot =2 ml).
After seven days viable splenocytes were isolated over a ficoll gradient and stained for H-2K To explore the short and long-term outcome of the CD8 + T-cell response after peptide vaccination with the minimal MHC class I binding peptides, mice were vaccinated with OVA8 in IFA and subsequently the secondary expansion potential of the CD8 + T-cells in vitro as well as the in vivo effector function were determined, either 10 days (short-term) or 30 days after vaccination (long-term). In addition a strong DC stimulus was provided by i.v.
injection of FGK in order to systemically activate APC in vivo (15, 16, 29) . Splenocytes were collected 10 days after vaccination and stimulated with OVA-expressing APC in vitro. The OVA-specific CD8 + T-cells in these cultures were capable of undergoing secondary expansion in vitro, as measured by high numbers of TM-OVA + CD8 + T-cells (Fig. 1A, left) . In order to determine whether vaccination resulted in effector CD8 + T-cells, an in vivo cytotoxicity assay was performed (30) . Both groups of mice vaccinated with OVA8 peptide in IFA (+/-FGK) displayed a similar capacity to kill target cells in vivo 10 days after vaccination (Fig. 1B, left) .
When splenocytes were isolated 30 days after vaccination, OVA-specific CD8 + T-cells displayed a strongly decreased capacity to undergo secondary expansion since only low numbers of OVA8-specific (TM-OVA + ) CD8 + T-cells could be observed after stimulation in vitro (Fig. 1A) . Accordingly, mice showed a markedly reduced capacity to kill target cells in vivo at day 30 ( Fig. 1B) , indicating that the ability to undergo secondary expansion in vitro correlated with the ability to lyse target cells in vivo. Provision of a DC stimulatory signal by FGK, although enhancing CTL levels at day 10, was unable to preserve the CTL response at day 30 (Figs 1A+B). Interestingly, when the OVA8 peptide was applied in PBS in combination with systemic administration of FGK, the CD8 + T-cell response was not lost over 30 days as indicated by their ability to expand after in vitro stimulation (Fig. 1A) and their capacity, albeit at lower levels, to kill target cells in vivo (Fig. 1B) . Thus, vaccination with the minimal OVA8 CTL peptide in IFA induces a transient effector CD8 + T-cell response, followed by functional impairment of these activated CD8 + T-cells.
Peptide vaccination in IFA induces long-term presentation of the minimal CTL peptide.
The major difference between PBS and IFA is the capacity of the latter formulation to function as a depot for the peptides. To test whether the OVA8 peptide in IFA was presented for a long term in vivo, mice were vaccinated with the OVA8 peptide in IFA and after either 30 or 60 days, CFSE-labeled OT-1 CD8 + T-cells were adoptively transferred into C57BL/6 mice as probes to detect antigen presentation in vivo. Extensive proliferation of OT-1 T-cells was observed both at day 30 and day 60 ( Fig. 2A ) in the dLN of vaccinated mice, indicating that the minimal OVA8 CTL peptide was still presented 60 days after vaccination. In contrast, when the peptide was applied in PBS, no proliferation of OT-1 CD8 + T-cells was observed at day 30 ( Fig. 2A) . This indicated that vaccination with the OVA8 peptide in PBS was associated with relatively short duration of Ag presentation, while vaccination in IFA induced long-term Ag presentation in vivo.
CD8+ T cell tolerance
Addition of Th OVA 323-339 peptide to the CTL/IFA vaccine retains CD8 + T-cell function.
Provision of FGK for APC activation (15, 16) , was unable to prevent CD8 + T-cell tolerance induction after vaccination with OVA8 peptide in IFA. As a dose of monoclonal Ab is generally rapidly cleared from the system (31,32), long-term presentation of OVA8 peptide beyond this period ( Fig. 2 ) occurs in the absence of a potent APC activating agent. Since CD4 + T-cells can also activate APC via CD40-CD40L interaction (33), the minimal Th peptide ThOVA17 was mixed into the same IFA depot as the OVA8 peptide. Adoptively transferred CFSE-labeled OT-2 cells into ThOVA17 vaccinated mice, showed that also the ThOVA17 peptide in IFA is presented for at least day 60 in vivo in the dLN (Fig. 2B) . We therefore tested if vaccination with ThOVA17 peptide in IFA was able to induce long-lasting OVA 323-339 -specific CD4 + T-cell responses in C57BL/6 mice. Indeed, OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] specific IFNγ + CD4 + T-cells could be detected in all mice when tested directly ex vivo, 30 days after vaccination with the ThOVA17 peptide in IFA (Fig. 3A) . Subsequently, we examined if Moreover, the combination with the ThOVA17 peptide retained the cytolytic capacity of these CD8 + T-cells at day 30 (compare Fig 3C and Fig 1B, respectively) .The addition of an extra DC-stimulatory signal, FGK, slightly enhanced the expansion of the OVA-specific CD8 + T-cell response (Fig.3B+C) . Injection of OVA8 and ThOVA17 in PBS, in combination with systemic injection of FGK, resulted in an OVA8-specific CD8 + T-cell response with a strong capacity to undergo secondary expansion but with only a moderate to kill target cells in vivo (Fig. 3B+C) .
Direct ex vivo analysis shows that at this time point the CD8 + T-cell response has contracted (% TM + CD8 + cells; 0.13±0.03 vs. naïve 0.12±0.04, data not shown), with too low numbers of circulating T-cells to exert a direct strong in vivo measurable cytotoxic response. In contrast to the T-cells that were formed after vaccination with OVA8 in IFA, delivery of OVA8 + FGK ± ThOVA17 in PBS did not affect their potential to expand in vitro following one round of stimulation (Fig. 1+3 ).
In conclusion, simultaneous activation of T-helper cells for the sustained deliverance of license to kill signals (34), prevented premature termination of the CD8 + T-cell response that is observed otherwise after vaccination with OVA8 in IFA.
CD8+ T cell tolerance 
Long CTL peptide induces long-lasting CD8
+ T-cell immunity independent of CD4+ T-cell help.
We have recently shown that long peptide-vaccination (35 a.a. long peptide) was superior to a minimal CTL peptide, with respect to the induction of the magnitude and functionality of the CD8 + T-cell response when vaccinated in PBS in combination with CpG-ODN (28).
To study whether the functional impairment of the CD8 + T-cell response induced by the minimal OVA8 CTL peptide in IFA can be prevented by the use of a longer peptide in IFA, a long CTL peptide OVA30 and the long ThOVA31 peptide were designed, using the natural OVA protein flanking residues to extend the minimal CTL and Th peptides. By use of TCR transgenic detector T-cells OT-1 (CD8) and OT-2 (CD4), we confirmed that also the extended CTL (OVA30) and Th (ThOVA31) peptides were presented at least for 60 days in vivo in the dLN, when administered in IFA (Fig. 4A+B ).
To ensure that vaccination with the ThOVA31 peptide also resulted in the induction of OVA-specific CD4 + T-cells, we enumerated the number of IFNγ producing CD4 + T-cells (Fig. 5C ).
The cytolytic activity of these CD8 + T cells was preserved over time, as a comparable killing capacity was observed at day 90 (Fig. 5D) . In addition to the vaccine draining lymph nodes, also the non-draining lymph nodes of mice injected with either OVA8, OVA30, ThOVA17 or ThOVA31 were analyzed for the presentation of these peptides. In contrast to the long peptides, which were presented predominantly in the draining lymph node, presentation of the OVA8 peptide was also observed in non-draining lymph nodes indicating that this peptide spreads systemically (Fig. 6) . Despite the fact that sustained presentation of the ThOVA17 peptide is readily detected in vivo (Fig.2B) , we were not able to detect presentation of the ThOVA17 peptide ex vivo (Fig. 6B) suggesting that the MHC class II off-rate of this peptide is too high to allow direct ex vivo detection. This must be related to the affinity of this peptide for MHC class II I-A b , which is probably lower than for the MHC class II molecule I-A d which was first found to present this peptide (35) .
Importantly, systemic presentation of OVA8 CTL peptide is associated with the functional impairment of the CD8 + T-cell response (Fig. 1B) while the predominant local presentation of the OVA30 peptide results in immunity. Therefore, we wondered what effect of OVA8 vaccination has on a concomitant immunogenic vaccination (OVA30, Fig. 5C ). To test this, mice were vaccinated with the OVA8 peptide, the OVA30 peptide or both peptides mixed in IFA and the in vivo killing capacity was determined at day 30. As shown in figure 7 , vaccination with OVA8 was unable to induce effector CD8 + T-cells at day 30, while vaccination with the OVA30 peptide resulted in a CTL response. When the OVA8 peptide was mixed with the OVA30 peptide in the same IFA depot, a significant reduction in the in vivo effector function of OVA-specific CD8 + T-cell reactivity was observed (Fig 7) . These data show that vaccination with the minimal OVA8 peptide has a dominant negative effect on the effector functions of CD8 + T-cell induced by an immunogenic peptide vaccine such as OVA30 CTL peptide. Failure to induce long-lasting CTL immunity is a more general characteristic of vaccination with minimal CTL peptide epitopes but can be overcome by the use of long peptides.
Because injection of the dominant minimal CTL peptide OVA8 of the model Ag OVA results in the functional impairment of CD8 + T cells when injected s.c. at a low dose in IFA, and as such acts similar to the earlier described adenoviral E1A (E1A10) (11, 17) and E1B (12) minimal CTL peptides, the impact of minimal and extended CTL epitope vaccines was compared in two additional antigenic systems.
First we tested the HPV16 E7 minimal CTL peptide (HPV9) and the extended CTL peptide (HPV35) (28) . As shown in Fig. 8A , vaccination with the HPV9 peptide resulted in marginal killing (8%) of HPV peptide loaded target cells in vivo 30 days after vaccination whereas the use of the HPV35 peptide resulted in 45% specific killing of target cells (Fig. 8A) . The enhanced effector response induced by HPV35 in IFA was independent of CD4 + T-cell help (Fig. 8A) .
Similarly, vaccination with the minimal CTL peptide of the Adenovirus E1A protein E1A10, known to tolerize the CD8 + T-cell response (11, 17) , failed to induce CD8 + T-cell effector function 30 days after vaccination (3% killing) (Fig. 8B) . In contrast, when the extended CTL peptide E1A30 was used 52% of the target cells were lysed 30 days after vaccination, independently of the presence of CD4 + T-cell help (Fig. 8B) . These results indicated that the use of extended CTL peptide vaccines may prevent T cell tolerance (E1A10 peptide) and, in general, induce a sustained in vivo CD8 + effector T-cell response, when compared to their minimal CTL peptide counterparts. 
CD8+ T cell tolerance

DISCUSSION
In this study we showed that vaccination with a low dose of a highly immunogenic exact When the minimal CTL peptide is administered in PBS, this antigen is presented to CD8 + T-cells for less than 30 days. In contrast, when the peptide is mixed with IFA, the CTL peptide was still presented at 60 days after vaccination. FGK is likely to be cleared rapidly from the system, similar to other Ab (31, 32) , and as such can only temporarily activate APC. When systemic presentation of the minimal CTL peptide ensues in the absence of a continuous helper/danger signal (36) , it is likely that this will result in CD8 + T-cell tolerance (Fig. 1, Fig.   2 and (17)). In order to provide continuous helper signals we included the minimal ThOVA17 peptide in the CTL/IFA bolus to activate APC via CD40-CD40L interactions (15, 16, 33) , and showed that also the Th peptide was presented for more than 60 days (Fig. 2) . As both peptides are continuously leaking out of the IFA depot, activation of APC, CD4 + and CD8 + T-cells will take place simultaneously. The induction of CD4 + T-cells not only enhanced the CD8 + T-cell response (Fig. 3) as was previously reported (37, 38) , but our experiments also show that it prevented the impairment of CD8 + T-cell reactivity, resulting in the preservation of long-term CD8 + T-cell immunity (Fig. 3) .
Recently, we found that the activation of CD8 Despite the fact that both the long OVA30 CTL peptide and the minimal OVA8 CTL peptide were presented for at least 60 days in vivo when applied in IFA (Fig. 4A and 2A, respectively) , vaccination with the OVA30 peptide did not result in an eventual impairment of CD8 + T-cell reactivity and did not require CD4 + T-cell help to preserve the CD8 + T-cell response (Fig. 5 ).
This was not only the case for OVA, but could be generalized for 3 Ag systems (Figs 1,5,8 ).
Extension of the minimal CTL peptide of either the OVA, HPV or E1A protein induced CD8 + T-cells with potent in vivo killing function until at least 30 days after vaccination.
Furthermore, increasing the length of the minimal E1A10 CTL peptide to a 30 a.a. long peptide, prevented the induction of CD8 + T-cell tolerance that was previously observed when the minimal CTL peptide was used (11) .
In contrast to the minimal CTL peptides -which spread systemically to non-draining and non-inflamed LNs (17, 29, 39) where antigen probably is presented in a tolerizing fashion (40) -the longer peptides are predominantly presented by APC in the vaccine dLN (Fig. 6) .
As IFA induces a local inflammatory response (41, 42) it will thereby provide the necessary danger signals (36, 43) that are needed to activate the local APC that have ingested the long peptide vaccine. Together, this can explain why vaccination with long peptides in IFA does not result in a functionally impaired CD8 + T-cell response and why CD4 + T-cell help is not required.
So, why did many papers report that minimal peptide vaccination in IFA induces an effective CD8 + T-cell response (6-9) instead of CD8 + T-cell tolerance? At one hand the outcome of vaccination was studied shortly after peptide vaccination when the CD8 + T-cells are not expected to be tolerized as shown here (Fig. 1A+B) . On the other, many of the peptides used were much longer than the minimal CTL sequence, reaching up to 27 a.a. in length (2, 6, 7, (44) (45) (46) (47) (48) , and/or contained a Th sequence (45, 49) . In view of the current results, this might explain why these so called "short synthetic peptides" performed so well compared to the exact minimal CTL peptides used here, or in clinical trials (4) .
In addition, it should be noted that vaccination with minimal CTL peptide represses the induction of CD8 + effector T-cells generated in response to concomitant proper antigen presentation (Fig. 7) . One can envisage that such an effect is highly undesirable in cancer patients that receive minimal CTL peptide vaccination after chemotherapy or radio therapy.
In these cases, large amounts of Ag are released and cross presented by DC (50) , which may result in the activation of tumor-specific CD8 + T cells that recognize the same sequences also present in the minimal CTL peptide vaccines in IFA. As a result such T-cell responses may be functional impaired following vaccination.
In conclusion, our data clearly answers the question why vaccines consisting of minimal CTL peptides in oil-in-water emulsions (e.g. IFA) may have only limited immunological and clinical success in cancer patients. These vaccines need to be complemented at least by T-helper epitopes in order to sustain effective CD8 + T-cell reactivity. In case that specific CD4 + T-cell help is not readily available, extension of CTL peptides to longer variants may form an excellent alternative. Vaccine trials should be performed in order to confirm our results in a human setting.
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